Need Assistance?

US & Canada:
+
UK: +

FAQs

Resources

Our Highlights

GMP Grade Efficient workshop for GMP production.
Optimal Prices Buying products on this site guarantees the best price!
Commercial Batches Independent GMP manufacturing suites that handle commercial batches
Prompt Delivery Warehouses in multiple cities to ensure timely delivery
Flexible Quantity Quantities available from milligrams to ton

Application Area

Micafungin sodium

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Micafungin Sodium is an inhibitor of 1,3-beta-D-glucan synthesis, used as an antifungal drug.

Category

Peptide APIs

Catalog number

BAT-010108

CAS number

208538-73-2

Molecular Formula

C56H70N9NaO23S

Molecular Weight

1292.25

Size	Price	Stock	Quantity
250 mg	$469	In stock

Specification
Reference Reading

IUPAC Name

sodium;[5-[(1S,2S)-2-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-3-[(1R)-3-amino-1-hydroxy-3-oxopropyl]-11,20,21,25-tetrahydroxy-15-[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-18-[[4-[5-(4-pentoxyphenyl)-1,2-oxazol-3-yl]benzoyl]amino]-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-6-yl]-1,2-dihydroxyethyl]-2-hydroxyphenyl] sulfate

Synonyms

FK463 Sodium; FK 463 Sodium; FK-463 Sodium; Mycamine; Funguard

Related CAS

235114-32-6 (free acid)

Appearance

White to Off-white Solid

Purity

>97%

Melting Point

>211°C

Storage

Store at -20°C

Solubility

Soluble in ethanol, methanol, DMF, DMSO

InChI

InChI=1S/C56H71N9O23S.Na/c1-4-5-6-17-86-32-14-11-28(12-15-32)39-21-33(63-87-39)27-7-9-29(10-8-27)49(75)58-34-20-38(70)52(78)62-54(80)45-46(72)25(2)23-65(45)56(82)43(37(69)22-41(57)71)60-53(79)44(48(74)47(73)30-13-16-36(68)40(18-30)88-89(83,84)85)61-51(77)35-19-31(67)24-64(35)55(81)42(26(3)66)59-50(34)76;/h7-16,18,21,25-26,31,34-35,37-38,42-48,52,66-70,72-74,78H,4-6,17,19-20,22-24H2,1-3H3,(H2,57,71)(H,58,75)(H,59,76)(H,60,79)(H,61,77)(H,62,80)(H,83,84,85);/q;+1/p-1/t25-,26+,31+,34-,35-,37+,38+,42-,43-,44-,45-,46-,47-,48-,52+;/m0./s1

InChI Key

KOOAFHGJVIVFMZ-WZPXRXMFSA-M

Canonical SMILES

CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC(=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC(=C(C=C7)O)OS(=O)(=O)[O-])O)O)C(CC(=O)N)O)C)O)O)O.[Na+]

1.Antifungal lock therapy with combined 70% ethanol and micafungin in a critically ill infant.

Piersigilli F1, Auriti C, Bersani I, Goffredo B, Bianco G, Savarese I, Dotta A. Pediatr Infect Dis J. 2014 Apr;33(4):419-20. doi: 10.1097/INF.0000000000000116.

So-called lock therapy, consisting of high concentrations of antimicrobials instilled into the lumen of the catheter, has been suggested avoid central venous catheter removal during fungal infection. We report a baby who developed catheter-related candidemia. Systemic antifungal treatment did not resolve the candidemia. Lock therapy with 0.3 mL of ethanol 70% and micafungin sodium 5 mg/L was added to the therapy, and blood cultures became sterile.

2.Comparison of the antifungal activity of micafungin and amphotericin B against Candida tropicalis biofilms.

Marcos-Zambrano LJ1, Escribano P2, Bouza E3, Guinea J4. J Antimicrob Chemother. 2016 May 4. pii: dkw162. [Epub ahead of print]

OBJECTIVES: Candida tropicalis is the fourth most common cause of candidaemia in hospitalized patients and associated mortality is high. C. tropicalis frequently causes biofilm-related infections. Echinocandins and amphotericin B show potent in vitro activity against C. albicans biofilms, but their activity against C. tropicalis biofilms has received little attention.

3.Prediction of micafungin area under the curve data by using peak concentration: applicability and utility in antifungal therapy

Srinivas NR1. Future Microbiol. 2016 Apr;11:485-90. doi: 10.2217/fmb.16.3. Epub 2016 Apr 12.

AIM: To describe a predictive model to obtain the area under the plasma concentration versus time curve (AUC) for micafungin to aid in dosing strategies in pediatric patients.